PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma

Completed · Phase 2

Conditions studied: Neoplasm

In brief

The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer. In order for tumors to grow and spread to other parts of the body, they need to have a growing blood supply. Tumor cells have been shown to produce substances that stimulate the abnormal growth of new blood vessels that allow the tumor to grow. In adults, blood vessel cells normally divide very rapidly. It is thought that PTK787/ZK222584 may interfere with the growth of new blood vessels. A drug that interferes with the growth of new blood vessels might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Since normal blood vessel cells divide very rarely, it might be possible to stop tumor growth without harming normal tissues.

Key facts

Study ID

NCT00226005

Run by

Pancreatic Cancer Research Team

People needed

67

Starts

2005-12-01

Expected to finish

2010-02-01

Last updated by the study team

2012-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18
• Zubrod performance status of 0 - 2
• Histological or cytological diagnosis of pancreatic adenocarcinoma
• Measurable or evaluable disease determined as per RECIST criteria
• Life expectancy > 12 weeks
• Written informed consent
• Patients must have failed or progressed on prior gemcitabine-based therapy for advanced or metastatic disease.

You may not qualify if…

• Islet cell or neuroendocrine carcinomas of the pancreas.
• History or presence of central nervous system disease.
• Patients with a history of another primary malignancy < 5 years
• Prior chemo therapy < 21 days prior to registration.
• Prior biologic or immunotherapy < 14 days prior to registration
• Prior full field radiotherapy < 28 days or limited field radiotherapy < 14 days prior to registration.
• Major surgery < 28 days prior to registration.
• Patients who have received investigational drugs < 28 days prior to registration.
• Prior therapy with anti-VEGF agents.
• Pleural effusion or ascites that causes respiratory compromise.
• Female patients who are pregnant or breast feeding.

Where it is running

• Scottsdale Healthcare — Scottsdale, Arizona, United States
• University of Arizona/Arizona Cancer Center — Tucson, Arizona, United States
• Tower Hematology Oncology Medical Group — Beverly Hills, California, United States
• Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins — Baltimore, Maryland, United States
• Virginia Piper Cancer Institute/Abbott Northwestern Hospital — Minneapolis, Minnesota, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• South Texas Oncology and Hematology — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.